RT Journal Article
SR Electronic
T1 778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A875
OP A875
DO 10.1136/jitc-2023-SITC2023.0778
VO 11
IS Suppl 1
A1 Olson, Daniel J
A1 Larkin, James
A1 Hong, Young
A1 Thomas, Sajeve
A1 Martin-Liberal, Juan
A1 Furness, Andrew JS
A1 Terheyden, Patrick
A1 In, Gino K
A1 Poklepovic, Andrew S
A1 Samhouri, Yazan
A1 Lammers, Philip
A1 Atkinson, Victoria
A1 Nguyen, Ryan H
A1 Peretz, Idit
A1 Butler, Marcus
A1 Finckenstein, Friedrich Graf
A1 Chou, Jeffrey
A1 Wu, Xiao
A1 Sulur, Giri
A1 Shi, Wen
A1 Haanen, John B
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A875.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.